Evidence map›Paper›PMID 26657215›Full record

ArticlePloS one2015

IFN-λ Inhibits MiR-122 Transcription through a Stat3-HNF4α Inflammatory Feedback Loop in an IFN-α Resistant HCV Cell Culture System.

Fatma Aboulnasr, Sidhartha Hazari, Satyam Nayak, Partha K Chandra, Rajesh Panigrahi, Pauline Ferraris, Srinivas Chava, Ramazan Kurt, Kyongsub Song, Asha Dash and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. IntrahepaticViruses · 2021
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Fatma AboulnasrPathology and Laboratory Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA-70112, United States of America.
Sidhartha HazariPathology and Laboratory Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA-70112, United States of America.
Satyam NayakPathology and Laboratory Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA-70112, United States of America.
Partha K ChandraPathology and Laboratory Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA-70112, United States of America.
Rajesh PanigrahiPathology and Laboratory Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA-70112, United States of America.
Pauline FerrarisPathology and Laboratory Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA-70112, United States of America.
Srinivas ChavaPathology and Laboratory Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA-70112, United States of America.
Ramazan KurtDepartment of Medicine, Division of Gastroenterology and Hepatology.
Kyongsub SongPathology and Laboratory Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA-70112, United States of America.
Asha DashPathology and Laboratory Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA-70112, United States of America.
Luis A BalartDepartment of Medicine, Division of Gastroenterology and Hepatology.
Robert F GarryMicrobiology and Immunology Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA-70112, United States of America.
Tong WuPathology and Laboratory Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA-70112, United States of America.
Srikanta DashPathology and Laboratory Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA-70112, United States of America.
Tulane University · US

Funding

Hepatitis C Virus and Hepatocellular CarcinomaR01CA089121 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI DASH, SRIKANTA · 2001 to 2016
$2.7M
IL-28B genotype and HCV treatment clearanceR01AI103106 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI DASH, SRIKANTA · 2013 to 2016
$1.5M
Hepatocarcinogenesis Secondary to Hepatitis CR01CA127481 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI DASH, SRIKANTA · 2008 to 2012
$1.4M
NCI NIH HHS CA089121NCI NIH HHS CA127481NCI NIH HHS R01 CA089121NCI NIH HHS R01 CA127481NIAID NIH HHS AI103106NIAID NIH HHS R01 AI103106
6 · The paper itself

Abstract

backgroundHCV replication in persistently infected cell culture remains resistant to IFN-α/RBV combination treatment, whereas IFN-λ1 induces viral clearance. The antiviral mechanisms by which IFN-λ1 induces sustained HCV clearance have not been determined.

aimTo investigate the mechanisms by which IFN-λ clears HCV replication in an HCV cell culture model.

methodsIFN-α sensitive (S3-GFP) and resistant (R4-GFP) cells were treated with equivalent concentrations of either IFN-α or IFN-λ. The relative antiviral effects of IFN-α and IFN-λ1 were compared by measuring the HCV replication, quantification of HCV-GFP expression by flow cytometry, and viral RNA levels by real time RT-PCR. Activation of Jak-Stat signaling, interferon stimulated gene (ISG) expression, and miRNA-122 transcription in S3-GFP and R4-GFP cells were examined.

resultsWe have shown that IFN-λ1 induces HCV clearance in IFN-α resistant and sensitive replicon cell lines in a dose dependent manner through Jak-Stat signaling, and induces STAT 1 and STAT 2 activation, ISRE-luciferase promoter activation and ISG expression. Stat 3 activation is also involved in IFN-λ1 induced antiviral activity in HCV cell culture. IFN-λ1 induced Stat 3 phosphorylation reduces the expression of hepatocyte nuclear factor 4 alpha (HNF4α) through miR-24 in R4-GFP cells. Reduced expression of HNF4α is associated with decreased expression of miR-122 resulting in an anti-HCV effect. Northern blot analysis confirms that IFN-λ1 reduces miR-122 levels in R4-GFP cells. Our results indicate that IFN-λ1 activates the Stat 3-HNF4α feedback inflammatory loop to inhibit miR-122 transcription in HCV cell culture.

conclusionsIn addition to the classical Jak-Stat antiviral signaling pathway, IFN-λ1 inhibits HCV replication through the suppression of miRNA-122 transcription via an inflammatory Stat 3-HNF4α feedback loop. Inflammatory feedback circuits activated by IFNs during chronic inflammation expose non-responders to the risk of hepatocellular carcinoma.

Indexed as

Antiviral AgentsCell Line, TumorFeedback, PhysiologicalGene Expression RegulationHepacivirusHepatocyte Nuclear Factor 4HepatocytesHost-Pathogen InteractionsHumansInterferon-alphaInterferon LambdaInterferonsInterleukinsJanus Kinase 1MicroRNAsPhosphorylationAntiviral AgentsHepatocyte Nuclear Factor 4HNF4A protein, humanInterferon-alphaInterferon Lambdainterferon-lambda, humanInterferonsInterleukinsJanus Kinase 1MicroRNAsMIRN122 microRNA, humanRibavirinRNA, ViralSTAT2 protein, humanSTAT2 Transcription FactorSTAT3 protein, humanSTAT3 Transcription Factor

Identifiers

PMID26657215
PMCPMC4686105
OpenAlexW2193454005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.